Literature DB >> 27461221

Impact of malignancy on Clostridium difficile infection.

M S Chung1, J Kim2, J O Kang3, H Pai4.   

Abstract

PURPOSE: The purpose of this study was to investigate the impact of malignancy and chemotherapy on the clinical and microbiological characteristics of Clostridium difficile infections (CDI).
METHODS: CDI patients with a history of malignancy within 5 years were defined as the cancer group. The characteristics of the patients were compared according to the presence of malignancy.
RESULTS: Of 580 patients with CDI, 159 (27.4 %) belonged to the cancer group and 421 (72.6 %) to the non-cancer group. More of the patients in the cancer group than those in the non-cancer group had been hospitalized within the prior 2 months (P < 0.001). Leukocytosis was more common in the non-cancer group (P = 0.034), while infection by PCR ribotype 017 strains was more common in the cancer group, with marginal significance (P = 0.07). Recurrence was more frequent in the cancer group (20.4 % vs. 9.5 %, P =0.005) and cancer was an independent risk factor for recurrence of CDI (OR = 2.66, 95 % CI 1.34-5.29, P =0.005). Age also contributed to the recurrence of CDI (OR = 1.03, 95 % CI 1.00-1.06, P =0.026).
CONCLUSIONS: Malignancy and age are independent risk factors for recurrence of CDI. Cancer patients require careful observation for recurrence after treatment of CDI.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27461221     DOI: 10.1007/s10096-016-2725-6

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  33 in total

1.  Risk factors associated with Clostridium difficile infection in adult oncology patients with a history of recent hospitalization for febrile neutropenia.

Authors:  Kenneth D Bishop; Jorge J Castillo
Journal:  Leuk Lymphoma       Date:  2012-01-31

Review 2.  Recurrent clostridium difficile.

Authors:  Seema Maroo; J Thomas Lamont
Journal:  Gastroenterology       Date:  2006-04       Impact factor: 22.682

3.  Predictors of mortality attributable to Clostridium difficile infection in patients with underlying malignancy.

Authors:  Young Kyung Yoon; Min Ja Kim; Jang Wook Sohn; Hye Suk Kim; Yoon Ji Choi; Jung Sun Kim; Seung Tae Kim; Kyong Hwa Park; Seok Jin Kim; Byung Soo Kim; Sang Won Shin; Yeul Hong Kim; Yong Park
Journal:  Support Care Cancer       Date:  2014-03-05       Impact factor: 3.603

4.  Host and pathogen factors for Clostridium difficile infection and colonization.

Authors:  Vivian G Loo; Anne-Marie Bourgault; Louise Poirier; François Lamothe; Sophie Michaud; Nathalie Turgeon; Baldwin Toye; Axelle Beaudoin; Eric H Frost; Rodica Gilca; Paul Brassard; Nandini Dendukuri; Claire Béliveau; Matthew Oughton; Ivan Brukner; Andre Dascal
Journal:  N Engl J Med       Date:  2011-11-03       Impact factor: 91.245

5.  New selective medium for isolating Clostridium difficile from faeces.

Authors:  S T Aspinall; D N Hutchinson
Journal:  J Clin Pathol       Date:  1992-09       Impact factor: 3.411

Review 6.  Recurrent Clostridium difficile infection: a review of risk factors, treatments, and outcomes.

Authors:  Stuart Johnson
Journal:  J Infect       Date:  2009-04-05       Impact factor: 6.072

7.  Gastrointestinal toxicity and Clostridium difficile diarrhea in patients treated with paclitaxel-containing chemotherapy regimens.

Authors:  A Husain; L Aptaker; D R Spriggs; R R Barakat
Journal:  Gynecol Oncol       Date:  1998-10       Impact factor: 5.482

8.  Risk factors, preemptive therapy, and antiperistaltic agents for Clostridium difficile infection in cancer patients.

Authors:  S G Krishna; W Zhao; S K Apewokin; K Krishna; P Chepyala; E J Anaissie
Journal:  Transpl Infect Dis       Date:  2013-08-27       Impact factor: 2.228

9.  Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study.

Authors:  Karen Barnett; Stewart W Mercer; Michael Norbury; Graham Watt; Sally Wyke; Bruce Guthrie
Journal:  Lancet       Date:  2012-05-10       Impact factor: 79.321

10.  Health care-associated Clostridium difficile infection in adults admitted to acute care hospitals in Canada: a Canadian Nosocomial Infection Surveillance Program Study.

Authors:  Denise Gravel; Mark Miller; Andrew Simor; Geoffrey Taylor; Michael Gardam; Allison McGeer; James Hutchinson; Dorothy Moore; Sharon Kelly; David Boyd; Michael Mulvey
Journal:  Clin Infect Dis       Date:  2009-03-01       Impact factor: 9.079

View more
  5 in total

1.  Prognosis of Clostridium difficile infection in adult oncohaematological patients: experience from a large prospective observational study.

Authors:  Isabel Ruiz-Camps; Benito Almirante; Thais Larrainzar-Coghen; Dolors Rodríguez-Pardo; Pere Barba; Juan Aguilar-Company; Virginia Rodríguez; Gloria Roig; Carmen Ferrer
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2018-08-02       Impact factor: 3.267

2.  Outcomes of Clostridioides difficile infection in adult cancer and non-cancer patients hospitalised in a tertiary hospital: a prospective cohort study.

Authors:  Bojana Milenković; Vesna Šuljagić; Aneta Perić; Viktorija Dragojević-Simić; Olivera Tarabar; Milomir Milanović; Vesna Putić; Diana Tomić; Branislava Miljković; Sandra Vezmar Kovačević
Journal:  Eur J Hosp Pharm       Date:  2021-02-12

3.  Risk Factors Associated With Recurrent Clostridium difficile Infection.

Authors:  Nikhita Dharbhamulla; Ahmed Abdelhady; Mona Domadia; Sanket Patel; John Gaughan; Satyajeet Roy
Journal:  J Clin Med Res       Date:  2018-12-03

4.  To study the contributing factors and outcomes of Clostridioides difficile infection in patients with solid tumors.

Authors:  Kamal Kant Sahu; Ajay Kumar Mishra; Vishal Jindal; Ahmad Daniyal Siddiqui; Susan V George
Journal:  Heliyon       Date:  2021-11-26

5.  Exploratory Evaluation of Bezlotoxumab on Outcomes Associated With Clostridioides difficile Infection in MODIFY I/II Participants With Cancer.

Authors:  Oliver A Cornely; Kathleen M Mullane; Thomas Birch; Sabine Hazan-Steinberg; Richard Nathan; Emilio Bouza; David P Calfee; Misoo Chung Ellison; Michael T Wong; Mary Beth Dorr
Journal:  Open Forum Infect Dis       Date:  2020-01-31       Impact factor: 3.835

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.